Supplementary Table S1. Kappa values for intraobserver reliability.
Assessment
Overall
PIP
MCP
Wrist
Elbow
Shoulder
Knee
Ankle
MTP
Greyscale
0.83
0.85
0.85
0.77
0.81
0.86
0.77
0.77
0.76
Power Doppler
0.87
0.91
0.91
0.81
0.82
0.65
0.70
0.75
0.88
Erosions
0.93
-
A kappa value of 0-0.2 was considered poor, 0.21-0.40 fair, 0.41-0.6 moderate, 0.61-0.8 good, and 0.81 to 1
excellent.
Supplementary Table S2. Distribution of clinical and US findings in joint areas by outcome.
Clinical joint area involvement, n (%)
PIP swelling
MCP swelling
Wrist swelling
Elbow swelling
Shoulder swelling
Knees swelling
Ankles swelling
MTP swelling
Clinical joint area symmetry, n (%)
PIP swelling
MCP swelling
Wrist swelling
Elbow swelling
Shoulder swelling
Knees swelling
Ankles swelling
MTP swelling
Greyscale joint area involvement, n (%)
PIP
MCP
Wrist
Elbow
Shoulder
Knees
Ankles
MTP
Greyscale joint area symmetry, n (%)
PIP
MCP
Wrist
Elbow
Shoulder
Knees
Ankles
MTP
Power doppler joint area involvement, n (%)
PIP
MCP
Wrist
Elbow
Shoulder
Knees
Ankles
MTP
Power doppler joint area symmetry, n (%)
PIP
MCP
Wrist
Elbow
Shoulder
Knees
Ankles
MTP
VERA
VENRA
Resolving
18 (62)
28 (97)
20 (69)
3 (10)
0
14 (48)
8 (28)
5 (17)
5 (39)
6 (46)
2 (15)
1 (8)
0
7 (54)
3 (23)
0
2 (12.5)
3 (19)
2 (12.5)
0
0
7 (44)
7 (44)
0
12 (41)
19 (66)
14 (48)
1 (3)
0
7 (24)
5 (17)
3 (10)
1 (38)
1 (8)
1 (8)
0
0
2 (15)
0
0
1 (6)
0
1 (6)
0
0
1 (6)
5 (31)
0
23 (79)
29 (100)
28 (97)
13 (45)
4 (14)
25 (86)
20 (69)
20 (69)
8 (62)
12 (92)
9 (69)
7 (53)
2 (15)
9 (69)
5 (38)
7 (54)
3 (19)
6 (37.5)
9 (50)
2 (12.5)
2 (12.5)
11 (69)
10 (62.5)
6 (37.5)
14 (48)
27 (93)
25 (86)
7 (24)
2 (7)
15 (52)
10 (34)
16 (55)
5 (38)
5 (38)
6 (46)
2 (15)
2 (15)
8 (62)
2 (15)
4 (31)
1 (6)
2 (12.5)
5 (31)
1 (6)
0
7 (44)
4 (25)
2 (12.5)
22 (76)
28 (96)
27 (93)
11 (38)
1 (3.4)
18 (62)
15 (52)
15 (52)
8 (62)
9 (69)
8 (62)
6 (46)
0
4 (31)
3 (23)
2 (15)
1 (6)
4 (25)
9 (56)
1 (6)
0
10 (62.5)
8 (50)
1 (6)
13 (45)
24 (83)
24 (83)
5 (17)
0
8 (28)
8 (28)
10 (34)
2 (15)
4 (31)
5 (38)
0
0
1 (8)
0
0
1 (6)
2 (12.5)
5 (31)
0
0
6 (37.5)
3 (19)
0
Supplemtary Table S3. Final outcome of patients identified by clinical and ultrasound 2010 RA
criteria.
Baseline clinical 2010 criteria, n = 26
Final diagnosis by 1987 criteria, n (%)
RA
PsA
SLE
Parvovirus
Pseudogout
Reactive
Septic
Unclassified
Baseline USGS 2010 criteria† n = 34
Final diagnosis by 1987 criteria, n (%)
RA
PsA
SLE
Parvovirus
Pseudogout
Reactive
Septic
Unclassified
Final clinical 2010 criteria, n = 25*
Final diagnosis by 1987 criteria, n (%)
RA
PsA
SLE
Parvovirus
Pseudogout
Reactive
Septic
Unclassified
VERA
24 (92)
0
0
0
0
0
0
0
VENRA
0
0
1 (4)
0
0
0
0
1 (4)
resolving
0
0
0
0
0
0
0
0
27 (79)
0
0
0
0
0
0
0
0
0
2 (6)
0
0
0
0
3 (9)
0
0
0
0
0
0
0
2 (6)
25 (96)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1 (4)
0
0
0
0
0
0
0
0
† Clinical examination variables have been replaced by ultrasonographic criteria of joint involvement (usgs≥1) and erosion
US: Ultrasound, GS: greyscale ultrasound
*Note that 2 patients developing SLE during follow-up are no longer classified as RA at 18 months according to ACR/EULAR
2010 criteria. Only one more patient is classified as having RA during this time period by 2010 criteria.